Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Blood blood.2024024968.

https://doi.org/10.1182/blood.2024024968

Published: 2024

Includes: Supplemental data

Journal Articles

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Blood (2023) 142 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2023-174891

Published: 2023

Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki

Blood (2023) 142 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2023-189340

Published: 2023

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

https://doi.org/10.1182/blood-2022-159391

Published: 2022

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 799–800.

https://doi.org/10.1182/blood-2022-165247

Published: 2022

Journal Articles

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Amanda Ranta, Tanja Ruokoranta, Annasofia Holopainen, Sirpa Koskela, Milla E.L. Kuusisto, Kimmo Porkka, Riikka Räty, Imre Västrik, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro

Blood (2021) 138 (Supplement 1): 228.

https://doi.org/10.1182/blood-2021-147691

Published: 2021

Journal Articles

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141345

Published: 2020

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2018-99-119880

Published: 2018

Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2743.

https://doi.org/10.1182/blood-2018-99-116391

Published: 2018

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Mahesh Tambe, PhD, Ella Karjalainen, MSc, Markus Vaha-Koskela, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2018-99-118289

Published: 2018

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Blood (2017) 130 (6): 789–802.

https://doi.org/10.1182/blood-2016-02-699363

Published: 2017

Includes: Supplemental data

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Corey Morales, BA, BS, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Bin Zhang, PhD, Claudia Kowolik, PhD, Mika Kontro, MD, Calum Leitch, MD, David Horne, PhD, Joycelynne Palmer, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2758.

https://doi.org/10.1182/blood.V128.22.2758.2758

Published: 2016

NARROW

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Predictive Response Biomarkers for BET Inhibitors in AML

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only